GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2007

Clinical Research Center of Cape Cod Will Aid Biomoda’s Work on Lung Cancer Detection Assay

  • Clinical Research Center of Cape Cod (CRCCC) will provide lung sputum samples for Biomoda’s investigation of its lung cancer detection tool. The technology is designed for cancer screening of large populations at a reasonable cost, Biomoda points out.

    The company’s noninvasive sputum assay is being investigated for the early detection of lung cancer. This technology is based on a porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. 

    “We are aggressively pursuing internal studies that, coupled with our clinical work with other organizations, will make our assay available to the public in the short term,” according to John Cousins, president of Biomoda. “CRCCC will help make that happen by supplying quality samples in a timely manner.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?